Kivo has launched Headless GxP, a new agent-native architecture designed to support compliant AI integration across drug development workflows. The platform aims to connect AI agents, regulated processes and authenticated human oversight within GxP-compliant environments.
API-first platform designed for regulated AI workflows
Kivo said the new Headless GxP architecture is built on its API-first document and process management platform for life sciences organisations.
The company stated that the system enables AI agents and external tools to access regulated content and workflow data while maintaining user authentication, audit trails and electronic signature requirements.
Human-authenticated oversight remains central
According to Kivo, the first release of Headless GxP is intentionally read-only. AI systems can analyse and interrogate regulated data, while compliance-related actions must still be reviewed and executed by authenticated users through Kivo’s validated interface.
The approach is designed to preserve regulatory requirements for electronic records and signatures while supporting AI-assisted workflows.
Potential applications across clinical and regulatory operations
Kivo outlined several potential use cases for the platform across regulated development environments. These include AI-assisted submission planning, automated cross-referencing of clinical study reports and quality impact analysis across controlled documents.
Furthermore, the platform is intended to support interoperability between different AI systems and life sciences software environments without compromising compliance requirements.
Growing focus on AI governance in life sciences
The launch reflects increasing industry focus on how generative AI and agentic systems can be integrated into regulated pharmaceutical and clinical workflows.
Importantly, life sciences companies continue to face pressure to balance innovation and automation with regulatory expectations surrounding data integrity, traceability and validated processes.
AI infrastructure evolving in drug development
As AI tools become more widely adopted across pharmaceutical research and development, companies are increasingly investing in infrastructure capable of supporting compliant AI operations.
Open architectures and API-based systems are gaining attention as organisations seek greater interoperability between data sources, workflow tools and emerging AI technologies.
Explore more in Digital Health & Health Tech.
